Tatva Chintan Pharma Chem
Tatva Chintan Pharma Chem Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Tatva Chintan Pharma Chem Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Tatva Chintan Pharma Chem Ltd trades at a P/E of 66.96× and P/B of 3.61×.
Valuation
Profitability
Growth
Financial Health
Tatva Chintan Pharma Chem Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Tatva Chintan Pharma Chem Ltd, switchable between annual and quarterly views, consolidated or standalone.
Tatva Chintan Pharma Chem Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,796.75 Cr and reported EPS of ₹18.01.
| Period | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue from Operations | 434 | 424 | 394 | 383 | 506 |
| Other Income | 9 | 6 | 8 | 2 | 4 |
| Total Income | 443 | 429 | 401 | 385 | 509 |
| Cost of Goods Sold (COGS) | 195 | 226 | 174 | 199 | 225 |
| Gross Profit | 239 | 198 | 219 | 184 | 281 |
| +Operating Expenses | 131 | 137 | 151 | 150 | 188 |
| EBITDA | 108 | 61 | 68 | 34 | 93 |
| +Non-Operating Expenses | 13 | 14 | 32 | 29 | 40 |
| Profit Before Tax (PBT) | 104 | 45 | 44 | 8 | 57 |
| +Tax Expense | 8 | -1 | 13 | 2 | 15 |
| Profit After Tax (PAT) | 96 | 45 | 30 | 6 | 42 |
| Earnings Per Share (EPS) | 43.25 | 20.52 | 12.98 | 2.44 | 17.98 |
| Diluted Shares Outstanding (Nos.) | 2 | 2 | 2 | 2 | 2 |
| +Additional Disclosures | 533 | 608 | 532 | 577 | 680 |
| Sales Growth % | — | -2.31 | -7.11 | -2.74 | 32.18 |
| YoY Sales Growth % | — | -2.31 | -7.11 | -2.74 | 32.18 |
| Material Cost % | 59 | 51 | 45 | 45 | 52 |
| Employee Cost % | 7 | 9 | 14 | 14 | 12 |
| Other Cost % | 23 | 23 | 24 | 25 | 25 |
| OPM % | 25 | 14 | 17 | 9 | 18 |
| Tax % | 8 | -2 | 30 | 25 | 26 |
| Profit Growth % | — | -52.56 | -33.27 | -81.18 | 636.11 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 100 | 51 | 43 | 7 | 56 |
Tatva Chintan Pharma Chem segment analysis: revenue and profit mix.
Disclosed business segments at Tatva Chintan Pharma Chem with their share of revenue and profit, switchable between consolidated and standalone reporting.
Tatva Chintan Pharma Chem discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Tatva Chintan Pharma Chem Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Tatva Chintan Pharma Chem Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Tatva Chintan Pharma Chem Ltd's investment case rests on 9 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter holding of 72% indicates high insider confidence and stability.
Very low debt-to-equity ratio of 0.05 ensures robust financial health.
Recent quarterly sales grew 10.80%, profit surged 27.60%, showing positive momentum.
Specialized product portfolio in SDAs, PTCs, and electrolyte salts offers niche expertise.
Diversified customer base across automotive, pharma, agrochemicals reduces revenue concentration risk.
What can break it.
Extremely high P/E ratio of 449.00 suggests significant overvaluation, increasing investment risk.
Very low Return on Equity (0.78%) indicates poor efficiency in generating shareholder profits.
Low Return on Capital Employed (1.20%) signals inefficient capital utilization and weak operations.
Negative EPS growth over 3Y (-62.02%) and 5Y (-32.20%) raises profitability concerns.
Negative annual cash flow per share (-22.06) indicates poor operational cash generation.
What would change my mind.
Trim if P/E re-rates above 87. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 15.90. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Tatva Chintan Pharma Chem Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Tatva Chintan Pharma Chem Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Tatva Chintan Pharma Chem Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Tatva Chintan Pharma Chem Ltd — derived from the live tape, not yesterday's close.
Tatva Chintan Pharma Chem Ltd last traded at ₹1,179.9 with an intraday range of ₹1,175.2–₹1,223.9 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1179.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1308.20 | +128.30 | +10.87% |
| R3 | 1259.50 | +79.60 | +6.75% |
| R2 | 1241.70 | +61.80 | +5.24% |
| R1 | 1210.80 | +30.90 | +2.62% |
| PIVOT | 1193.00 | 13.10 | 1.11% |
| CURRENT | 1179.90 | — | — |
| S1 | 1064.70 | -115.20 | -9.76% |
| S2 | 1113.40 | -66.50 | -5.64% |
| S3 | 1144.30 | -35.60 | -3.02% |
| S4 | 1162.10 | -17.80 | -1.51% |
TATVA is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 1203.5 ~ 1223.9
Trading Inside opening range
Tatva Chintan Pharma Chem Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Tatva Chintan Pharma Chem Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Tatva Chintan Pharma Chem Ltd stood at 46.6% of traded volume, against a 20-day average of 49.1%.
Tatva Chintan Pharma Chem announcements: results, concalls, ratings, M&A.
Filings Tatva Chintan Pharma Chem sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Tatva Chintan Pharma Chem files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 111 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet
Disclosure under SEBI Takeover Regulations
Shekhar Rasiklal Somani has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Disclosure under SEBI Takeover Regulations
Tatva Chintan Pharma Chem Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of…
Disclosure under SEBI Takeover Regulations
Ajay Mansukhlal Patel has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Analysts/Institutional Investor Meet/Con. Call Updates
Tatva Chintan Pharma Chem Limited has informed the Exchange about Transcript
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Tatva Chintan Pharma Chem dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Tatva Chintan Pharma Chem has declared, sequenced by announce and record date.
Tatva Chintan Pharma Chem corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Tatva Chintan Pharma Chem Ltd: business, sector, key facts.
What Tatva Chintan Pharma Chem Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Tatva Chintan Pharma Chem Ltd operates in the Basic Materials, listed as NSE: TATVA, BSE: 543321.
Tatva Chintan Pharma Chem Limited (TCPL) is a prominent Indian manufacturer and supplier of specialty chemicals, catering to both domestic and international markets. Their business model centers on providing high-quality, specialized chemical compounds for a diverse range of industrial applications. This specialization distinguishes them within the broader chemical industry, allowing them to focus on niche markets and develop strong expertise in their chosen areas.
A core component of TCPL's product portfolio lies in structure-directing agents (SDAs) used in the synthesis of zeolites. Zeolites are crystalline aluminosilicate minerals with various industrial applications, and TCPL's SDAs play a crucial role in controlling the structure and properties of these materials. This demonstrates their involvement in a technologically advanced segment of the chemical industry requiring sophisticated chemical engineering and synthesis expertise.
Beyond zeolite synthesis, TCPL produces and distributes a wide array of other specialty chemicals. This includes phase-transfer catalysts, which accelerate chemical reactions; electrolyte salts for cutting-edge energy storage technologies like supercapacitors and zinc-ion batteries; and various pharmaceutical and agrochemical products. This broad product range underscores their ability to adapt to evolving market demands and serve multiple sectors.
The company's customer base spans a multitude of industries, highlighting the versatility of their chemical offerings. These include the automotive sector, refineries, pharmaceutical manufacturers, agrochemical producers, manufacturers of paints and coatings, dyes and pigments, personal care products, and companies in the flavor and fragrance industries. This widespread reach indicates the diverse applications of their specialized chemicals and their success in penetrating significant market segments.
In summary, Tatva Chintan Pharma Chem Limited operates a successful business focused on the manufacturing and sale of high-value specialty chemicals. Their expertise in specific areas, coupled with a diversified customer base and a broad product portfolio, positions them as a significant player within the global chemical industry. The company's continued focus on innovation and adaptation to emerging technological needs ensures their continued relevance and growth prospects within the market.
Questions investors ask about Tatva Chintan Pharma Chem Ltd (TATVA).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Tatva Chintan Pharma Chem Ltd (TATVA)?
The current share price of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹1,179.9. Today, the stock has declined by ₹28.50 (2.36%), trading in a range of ₹1,175.2 to ₹1,223.9. The stock opened at ₹1,203.5 with a trading volume of 31,031 shares.
02Is Tatva Chintan Pharma Chem Ltd stock a good investment for long-term?
Tatva Chintan Pharma Chem Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,796.75 crores, P/E ratio of 66.96, ROE of 5.53%, and ROCE of 1.20%. The dividend yield stands at 0.08%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Tatva Chintan Pharma Chem Ltd stock?
The 52-week high price of Tatva Chintan Pharma Chem Ltd (TATVA) is ₹1,610, while the 52-week low is ₹886. Currently trading at ₹1,179.9, the stock is 40.6% away from its 52-week low and 26.7% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Tatva Chintan Pharma Chem Ltd stock at the current price?
Whether to buy Tatva Chintan Pharma Chem Ltd stock at ₹1,179.9 depends on multiple factors. The stock is currently trading with a P/E ratio of 66.96 and P/B ratio of 3.61. Today's performance shows a loss of 2.36%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Tatva Chintan Pharma Chem Ltd and when is the next dividend?
Tatva Chintan Pharma Chem Ltd offers a dividend yield of 0.08%, which means for every ₹100 invested at the current price of ₹1,179.9, you can expect to receive approximately ₹0.08 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Tatva Chintan Pharma Chem Ltd?
Tatva Chintan Pharma Chem Ltd's key financial metrics include: P/E Ratio: 66.96, P/B Ratio: 3.61, ROE: 5.53%, ROCE: 1.20%, Dividend Yield: 0.08%, EPS: ₹18.01, Book Value: ₹334.03, and Debt-to-Equity: 15.40. The company's market cap stands at ₹2,796.75 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Tatva Chintan Pharma Chem Ltd stock performing today in the market?
Tatva Chintan Pharma Chem Ltd stock opened at ₹1,203.5 and is currently trading at ₹1,179.9, showing a decline of ₹28.50 (2.36%). The intraday high is ₹1,223.9 and low is ₹1,175.2. The trading volume stands at 31,031 shares, indicating moderate market participation today.
08What is the P/E ratio of Tatva Chintan Pharma Chem Ltd and what does it indicate?
Tatva Chintan Pharma Chem Ltd has a Price-to-Earnings (P/E) ratio of 66.96, which means investors are willing to pay ₹66.96 for every ₹1 of earnings. With an EPS of ₹18.01, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Tatva Chintan Pharma Chem Ltd (TATVA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarti Industries (AARTIIND) Share PricePeer
- Aarti Surfactants (AARTISURF) Share PricePeer
- Archean Chemical Industries (ACI) Share PricePeer
- Aether Industries (AETHER) Share PricePeer
- Alkali Metals (ALKALI) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy